Abstract:Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are characterized by chronic idiopathic inflammation of gastrointestinal tract. Although the pathogenesis of IBD remains unknown, intestinal immune dysfunction has been considered as the core pathogenesis. In the intestinal immune system, T helper 1 (Th1) and Th17 cells are indispensable for intestine homeostasis via preventing pathogenic bacteria invasion, regulating metabolism and functions of intestinal epithelial cells (IECs), and promoting IEC self-renewal. However, during the development of IBD, Th1 and Th17 cells acquire the pathogenicity and change from the maintainer of intestinal homeostasis to the destroyer of intestinal mucosa. Because of coexpressing interferon-γ and interleukin-17A, Th17 cells with pathogenicity are named as pathogenic Th17 cells. In disease states, Th1 cells impair IEC programs by inducing IEC apoptosis, recruiting immune cells, promoting adhesion molecules expression of IECs, and differentiating to epithelial cell adhesion molecule-specific interferon γ-positive Th1 cells. Pathogenic Th17 cells induce IEC injury by triggering IBD susceptibility genes expression of IECs and specifically killing IECs. In addition, Th1 and pathogenic Th17 cells could cooperate to induce colitis. The evidences from IBD patients and animal models demonstrate that synergistic action of Th1 and pathogenic Th17 cells occurs in the diseases development and aggravates the mucosal inflammation. In this review, we focused on Th1 and Th17 cell programs in homeostasis and intestine inflammation and specifically discussed the impact of Th1 and Th17 cell pathogenicity and their synergistic action on the onset and the development of IBD. We hoped to provide some clues for treating IBD.

T helper cell subsets, key cytokines and chemokines in the pathogenesis of inflammatory bowel disease (Part 1)

Potential Role of Th17 Cells in the Pathogenesis of Inflammatory Bowel Disease.

Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease.

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases

Dysregulation of T cell response in the pathogenesis of inflammatory bowel disease

A comprehensive immunobiology review of IBD: With a specific glance to Th22 lymphocytes development, biology, function, and role in IBD

Interplay of Intestinal Microbiota and Mucosal Immunity in Inflammatory Bowel Disease: a Relationship of Frenemies

The Involvement of TH17 Cells in the Pathogenesis of IBD

CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease

TH17 cell: a double-edged sword in the development of inflammatory bowel disease

The role of Th17 cells in inflammatory bowel disease and the research progress

Th17,Th17 Cytokines and Inflammatory Bowel Disease

Synergy of IL-23 and Th17 Cytokines: New Light on Inflammatory Bowel Disease

Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease

After Interleukin-12P40, Are Interleukin-23 and Interleukin-17 the Next Therapeutic Targets for Inflammatory Bowel Disease?

The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease

Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation

Current, experimental, and future treatments in inflammatory bowel disease: a clinical review

TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota

The Role of Innate and Adaptive Immune Cells in the Pathogenesis and Development of the Inflammatory Response in Ulcerative Colitis